Richmond Chemical Corporation’s Bio-Nanotechnology R&D Division

In the next ten years, Nanotechnology is expected to affect up to 80% of the traditional lifescience industry and Life and Bioscience oriented research. Many current approaches to diagnostics and health care include use of nanodevices, nanoparticles and nanoanalytic systems, a development which shows promises for improved delivery and effectiveness of traditional medical treatments. These have revolutionized future perspectives of pharmaceutical drug discovery and development. One aspect of drug discovery that nanotechnology may improve is the cost of drug development, thus the cost of pharmaceutical design would be reduced and drugs may be available for treatment much faster.


Richmond Chemical Corporation's nanotechnology division is dedicated to development of nanodevices for lifescience applications such as targeted therapeutics and drug screening, and nanoanalysis of biological systems using single molecule imaging and force spectroscopy. Core nanoanalysis instrumentation includes state of the art Atomic Force Microscopy integrated with Fluorescence Microscopy, with the ability to image single biomolecules and their interactions, as well as live cells in their physiological environment during online addition of target molecules. Measuring the interaction and binding force between single biomolecules and between cells and biomolecules is another strength of multimodal AFM. This allows for ultra sensitive detection of key biomarkers for disease diagnosis, prognosis and monitoring.